M. Karuppasamy

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes

B. Sahoo, Manojkumar Mahapatra, Muthukumar Karuppasamy, 2022, Reviews in Endocrine and Metabolic Disorders.

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review

B. Sahoo, Manojkumar Mahapatra, Muthukumar Karuppasamy, 2022, Pharmaceutical Research.

Fundamental considerations in drug design

Manojkumar Mahapatra, Muthukumar Karuppasamy, M. Karuppasamy, 2022, Computer Aided Drug Design (CADD) : from Ligand-Based Methods to Structure-based Approaches.

DOCK3 regulates normal skeletal muscle regeneration and glucose metabolism

J. Widrick, Adrienne Samani, Yimin Wang, 2023, bioRxiv.

Standardization of zebrafish drug testing parameters for muscle diseases

J. Parant, L. Maves, A. Ruparelia, 2024, Disease models & mechanisms.